Walsh, J. A.
Gottlieb, A. B.
Hoepken, B.
Nurminen, T.
Mease, P. J.
Funding for this research was provided by:
UCB Pharma
Article History
Received: 24 May 2018
Accepted: 20 July 2018
First Online: 6 September 2018
Change Date: 11 October 2018
Change Type: Correction
Change Details: The above article originally published with an error present in Discussion section and presented correctly in this article. The original article was corrected.
Compliance with ethical standards
:
: JAW: Consultancies: Abbott, Celgene, UCB Pharma, and Novartis; ABG: Consultancies, speaking fees and honoraria: AbbVie, Janssen, Eli Lilly, Novartis, UCB Pharma, Allergan, Sienna, BMC, Sun Pharma; BH: Employee of UCB Pharma; TN: Employee of UCB Pharma; PJM: Research grants: AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, UCB Pharma; Consultancies: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, UCB Pharma; Speakers’ bureau: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Novartis, Pfizer, UCB Pharma.
: UCB sponsored the study and the development of the manuscript and reviewed the text to ensure that from a UCB perspective, the data presented in the publication are scientifically, technically, and medically supportable, that they do not contain any information that has the potential to damage the intellectual property of UCB, and that the publication complies with applicable laws, regulations, guidelines, and good industry practice. The authors approved the final version to be published after critically revising the manuscript for important intellectual content.